Literature DB >> 10415542

Optimal myocardial preconditioning in humans.

G Cohen1, T Shirai, R D Weisel, V Rao, F Merante, L C Tumiati, M K Mohabeer, M A Borger, R K Li, D A Mickle.   

Abstract

We developed a model of ischemia and reperfusion (I and R) in human ventricular myocytes (CM). CM injury and metabolics were studied after various interventions: endogenous preconditioning (PC) with anoxia, hypoxia, and anoxic or hypoxic supernatants; endogenous PC with or without SPT or adenosine deaminase; and exogenous adenosine PC before, during, or after I or continuously, with or without SPT. To assess the clinical implications of PC and the possible mediating effects of adenosine, patients undergoing elective coronary bypass surgery (CABG) received either a high or low dose of adenosine. Patients not receiving adenosine served as controls. Adenosine levels, high-energy phosphate levels, the metabolic parameters were evaluated from blood samples and left ventricular biopsy samples. Our cellular model studies indicated that preconditioning conferred protection to human CM via an adenosine-mediated pathway. Adenosine simulated PC without a fall in ATP. Adenosine administered to patients during CABG stimulated myocardial metabolism while preventing the degradation of high energy phosphates. A prospective randomized trial of adenosine administered to high-risk patients for myocardial protection is required.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415542     DOI: 10.1111/j.1749-6632.1999.tb09246.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Adenosine in cold blood cardioplegia--a placebo-controlled study.

Authors:  Anders Ahlsson; Claudio Sobrosa; Lennart Kaijser; Eva Jansson; Vollmer Bomfim
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15

2.  A human in vitro platform for the evaluation of pharmacology strategies in cardiac ischemia.

Authors:  Carlota Oleaga; Golareh Jalilvand; Gregg Legters; Candace Martin; Gail Ekman; Christopher W McAleer; Christopher J Long; James J Hickman
Journal:  APL Bioeng       Date:  2019-08-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.